NCT03564197View on ClinicalTrials.gov

18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC

NARecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 25, 2018

Primary Completion Date

December 30, 2023

Study Completion Date

December 30, 2024

Conditions
NSCLC Stage IV
Interventions
OTHER

18F-PD-L1

18F-PD-L1 PET/CT scan

Trial Locations (8)

Unknown

RECRUITING

Jeroen Bosch Ziekenhuis, 's-Hertogenbosch

RECRUITING

MeanderMC, Amersfoort

RECRUITING

Deventer Ziekenhuis, Deventer

RECRUITING

LUMC, Leiden

RECRUITING

Medisch Centrum Haaglanden, The Hague

RECRUITING

Antonius Ziekenhuis, Utrecht

1007 MB

NOT_YET_RECRUITING

VUmc, Amsterdam

1060CX

RECRUITING

Antoni van Leeuwenhoek, Amsterdam

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER